Aspirin resistance and diabetes mellitus

[1] Cubbon RM(2007)Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003 Eur Heart J 28 540-545

[2] Wheatcroft SB(2007)AHA/ADA vs ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions Eur Heart J 28 1925-1927

[3] Grant PJ(2002)Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 71-86

[4] Nicolucci A(2003)Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial Diabetes Care 26 3264-3272

[5] De Berardis G(2005)Aspirin resistance and atherothrombotic disease J Am Coll Cardiol 46 986-993

[6] Sacco M(2005)Narrative review: aspirin resistance and its clinical implications Ann Intern Med 142 370-380

[7] Tognoni G(1978)Acetylation of the NH J Biol Chem 253 3782-3784

[8] Sacco M(1985)-terminal serine of prostaglandin synthetase by aspirin Circulation 72 1177-1184

[9] Pellegrini F(1986)Clinical pharmacology of platelet cyclooxygenase inhibition Prostaglandins 32 415-423

[10] Roncaglioni MC(1989)Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man Circulation 80 198-205

[1] Cubbon RM(2007)Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003 Eur Heart J 28 540-545

[2] Wheatcroft SB(2007)AHA/ADA vs ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions Eur Heart J 28 1925-1927

[3] Grant PJ(2002)Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 71-86

[4] Nicolucci A(2003)Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial Diabetes Care 26 3264-3272

[5] De Berardis G(2005)Aspirin resistance and atherothrombotic disease J Am Coll Cardiol 46 986-993

[6] Sacco M(2005)Narrative review: aspirin resistance and its clinical implications Ann Intern Med 142 370-380

[7] Tognoni G(1978)Acetylation of the NH J Biol Chem 253 3782-3784

[8] Sacco M(1985)-terminal serine of prostaglandin synthetase by aspirin Circulation 72 1177-1184

[9] Pellegrini F(1986)Clinical pharmacology of platelet cyclooxygenase inhibition Prostaglandins 32 415-423

[10] Roncaglioni MC(1989)Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man Circulation 80 198-205